Theranostic application of (64)Cu/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.
Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, Zhou D, Wang R, Gong J, Miao Q, Kang L, Yang J.
Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):168-183. doi: 10.1007/s00259-022-05954-y. Epub 2022 Sep 5.
Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model.
Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K, Toyoshima A, Nagata K, Haberkorn U, Kratochwil C, Shinohara A, Hatazawa J, Giesel F.
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):871-880. doi: 10.1007/s00259-021-05554-2. Epub 2021 Sep 18.
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [1771772.
Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Bal C.
Pharmaceuticals (Basel). 2021 Nov 24;14(12):1212. doi: 10.3390/ph14121212.
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
Hetero-bivalent agents targeting FAP and PSMA.
Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, Shin MJ, Merino VF, Zheng L, Brayton C, Pomper MG, Banerjee SR.
Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4369-4381. doi: 10.1007/s00259-022-05933-3. Epub 2022 Aug 15.
ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer.
Chen W, Li M, Younis MH, Barnhart TE, Jiang D, Sun T, Lang JM, Engle JW, Zhou M, Cai W.
Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):861-870. doi: 10.1007/s00259-021-05563-1. Epub 2021 Sep 14.
Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013.
Tan Y, Li J, Zhao T, Zhou M, Liu K, Xiang S, Tang Y, Jakobsson V, Xu P, Chen X, Zhang J.
Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2761-2773. doi: 10.1007/s00259-024-06703-z. Epub 2024 Apr 2.
Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.
Murakami T, Fujimoto H, Hamamatsu K, Yamauchi Y, Kodama Y, Fujita N, Fujikura J, Shimizu Y, Nakamoto Y, Kimura H, Saji H, Inagaki N.
Sci Rep. 2021 Jul 22;11(1):15014. doi: 10.1038/s41598-021-94595-6.
89Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe.
Fung K, Vivier D, Keinänen O, Sarbisheh EK, Price EW, Zeglis BM.
Molecules. 2020 May 15;25(10):2315. doi: 10.3390/molecules25102315.
Synthesis and Preclinical Evaluation of Radiolabeled [103Ru]BOLD-100.
Happl B, Brandt M, Balber T, Benčurová K, Talip Z, Voegele A, Heffeter P, Kandioller W, Van der Meulen NP, Mitterhauser M, Hacker M, Keppler BK, Mindt TL.
Pharmaceutics. 2023 Nov 15;15(11):2626. doi: 10.3390/pharmaceutics15112626.
